GrifolsMEX:GRFP N 83 FCF Yield % is 10.97 as of Jun. 25, 2026, which is 319% above its 10-year median of 2.62. GuruFocus rates MEX:GRFP N with a GF Score™ of 83/100 and a GF Value™ of MXN154.24. The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Grifols ranks better than 88.86% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Grifols's Trailing 12-Month Free Cash Flow is MXN12,762 Mil, and Market Cap is MXN108,532 Mil. Therefore, Grifols's FCF Yield % for today is 10.97%.
The historical rank and industry rank for Grifols's FCF Yield % or its related term are showing as below:
MEX:GRFP N'
s FCF Yield % Range Over the Past 10 Years
Min: 0.66 Med: 2.62 Max: 10.97
Current: 10.97
During the past 13 years, the highest FCF Yield % of Grifols was 10.97%. The lowest was 0.66%. And the median was 2.62%.
MEX:GRFP N's FCF Yield % is ranked better than 88.86% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs MEX:GRFP N: 10.97
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Grifols FCF Yield % Related Terms
Grifols FCF Yield % Historical Data
* Premium members only.
The historical data trend for Grifols's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GRFP N vs LLY, JNJ, ABBV: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Grifols's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Grifols's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a FCF Yield % of 10.97 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Grifols and its competitors. This is 319% above median its historical median of 2.62. Over the past decade, Grifols' FCF Yield % has ranged from 0.66 to 10.97. According to the industry distribution chart, Grifols ranks #112 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Grifols' FCF Yield % too high?
Grifols' current FCF Yield % of 10.97 is 319% above median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 10.97. The Drug Manufacturers industry median FCF Yield % is 0.67. Grifols' value of 10.97 is 1537.3% above this industry median. Based on the distribution chart, Grifols ranks #112 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #112 out of 1005 companies for FCF Yield %. This places Grifols in the top 11% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Grifols' value of 10.97 is 1537.3% above this benchmark. Historically, Grifols' own FCF Yield % has ranged from 0.66 to 10.97 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 0.67, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current FCF Yield % of 10.97 is 1537.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current FCF Yield % is 10.97, which is 319% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current FCF Yield % of 10.97. The stock's GF Value™ is MXN154.24, compared to a current price of MXN126.63 — trading 17.9% below its estimated fair value. The current FCF Yield % is 10.97, which is 319% above median its 10-year median of 2.62 and 1537.3% above the Drug Manufacturers industry median of 0.67. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current FCF Yield % is 10.97 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.9% below its estimated GF Value™ of MXN154.24.
Key valuation signals for MEX:GRFP N:
FCF Yield %: 10.97 (319% above median its 10-year median of 2.62)
GF Value™: MXN154.24 vs. price of MXN126.63 (17.9% below fair value)
Industry Position: 1537.3% above the Drug Manufacturers median (#112 of 1005)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for MEX:GRFP N
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
